Agenus, Inc., an immunology company that creates novel treatments for cancers and similar diseases, said Wednesday that C. Evan Ballantyne will be its new chief financial officer.
Ballantyne has over 30 years of experience with financial and operational work. Previously, he was chief financial officer at Synthetic Biologics, Inc., a publicly traded biotechnology company. He has also worked at Clinical Data as the executive vice president and chief financial officer. He also has served as chief financial officer at ZymeQuest, Inc. and Avedro, Inc.
“We are pleased to welcome Evan as our chief financial officer,” Agenus Chariman and CEO Garo Armen said. “Evan has had a distinguished career, and we look forward to his contributions to the continued growth of our company.”
Ballantyne's appointment is effective immediately. He will be responsible for Agenus' accounting, financial, corporation communication and investor relations functions.
“This is a very exciting time for Agenus, and I look forward to working with the management team as the company continues to advance its immuno-oncology platform technologies and product candidate pipeline and further develop its partnership opportunities,” Ballantyne said.